title: Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation.
abstract: OBJECTIVE
  Human serum paraoxonase 1 (PON1) activity is inversely related to the risk of developing an atherosclerotic lesion, which contains cholesterol-loaded macrophage foam cells. To assess a possible mechanism for this relationship, we analyzed the effect of PON1 on cellular cholesterol biosynthesis.
  
  
  RESULTS
  Mouse peritoneal macrophages (MPMs) were harvested from PON1-deficient mice (PON1o and PON1o/Eo mice on the genetic background of C57BL/6J and Eo mice, respectively). PON1o/Eo mice exhibited a significantly 51% increased atherosclerotic lesion area and 35% increased macrophage cholesterol content compared with control E degrees mice. In parallel, macrophage cholesterol biosynthesis rates were increased in PON1-deficient mice MPMs by 50% compared with their controls. Incubation of macrophages with human PON1 revealed a dose-dependent inhibitory effect (up to 84%) on macrophage cholesterol biosynthesis. We demonstrated a PON1 phospholipase-A2-like activity on MPMs, evidenced by release of polyunsaturated fatty acids and formation of lysophosphatidylcholine. On incubation of macrophages with lysophosphatidylcholine, a dose-dependent inhibition (up to 40%) of cellular cholesterol biosynthesis was noted. The inhibitory effect of PON1 on macrophage cholesterol biosynthesis was shown to be downstream to mevalonate, probably at the lanosterol metabolic point.
  
  
  CONCLUSIONS
  PON1 inhibits macrophage cholesterol biosynthesis and atherogenesis probably through its phospholipase-A2-like activity.
authors.affiliation: Technion Faculty of Medicine, The Rappaport Institute for Research in Medical Sciences, Rambam Medical Center, Haifa.
authors.forename: Orit
authors.initials: O
authors.lastname: Rozenberg
authors.forename: Diana M
authors.initials: DM
authors.lastname: Shih
authors.forename: Michael
authors.initials: M
authors.lastname: Aviram
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism*; D043303:Aryldialkylphosphatase; D016466:CHO Cells; D002417:Cattle; D002478:Cells, Cultured; D002784:Cholesterol / Q000096:biosynthesis*; D008076:Cholesterol, HDL / Q000096:biosynthesis; D006224:Cricetinae; D004950:Esterases / Q000097:blood* / Q000172:deficiency / Q000235:genetics; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D008244:Lysophosphatidylcholines / Q000096:biosynthesis*; D017737:Macrophages, Peritoneal / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D012333:RNA, Messenger / Q000032:analysis
chemical_list: D008076:Cholesterol, HDL; D005227:Fatty Acids; D008244:Lysophosphatidylcholines; D012333:RNA, Messenger; D002784:Cholesterol; D004950:Esterases; D010741:Phospholipases A; D054467:Phospholipases A2; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human